# Ficlatuzumab

Source: https://onco.cc/drugs/ficlatuzumab/  
OnCo record `ficlatuzumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ficlatuzumab is an experimental monoclonal antibody from AVEO Pharmaceuticals in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.

## Summary

Ficlatuzumab (AV-299) is a monoclonal antibody developed by AVEO Pharmaceuticals. The sponsor describes its target as HGF (hepatocyte growth factor), which OnCo does not yet have a target page for. The sponsor states: A humanized hepatocyte growth factor (HGF) inhibitory IgG1 monoclonal antibody that blocks HGF signalling, distinct from EGFR-targeted agents such as cetuximab. ClinicalTrials.gov describes the intervention as: Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06064877 (A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma), in head and neck squamous cell carcinoma. The largest, NCT06064877, plans to enrol 410 participants with primary completion expected 2027-08. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: AV-299
- Modality: monoclonal antibody
- Mechanism: A humanized hepatocyte growth factor (HGF) inhibitory IgG1 monoclonal antibody that blocks HGF signalling, distinct from EGFR-targeted agents such as cetuximab.

## Sources

- ClinicalTrials.gov: trials of Ficlatuzumab: https://clinicaltrials.gov/search?intr=AV-299

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- companies: [AVEO Oncology (LG Chem)](https://onco.cc/companies/aveo/)
- trials: [A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct06064877/)
- targets: [HGF](https://onco.cc/targets/hgf/)

---
JSON: https://onco.cc/api/v1/entities/ficlatuzumab.json